Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Dosage Form
3.3. Snippet by Treatment Type
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the Clinical Trails by the Key Players
4.1.1.2. Strong Pipeline of Products Showing Promising Results
4.1.2. Restraints
4.1.2.1. High Cost of Disease Management
4.1.3. Opportunity
4.1.3.1. Development of effective treatments to combat and prevent RSV infections
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario before COVID-19
6.1.2. Scenario during COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Impact Analysis
9. By Drug Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.1.2. Market Attractiveness Index, By Drug Type
9.2. Ribavirin
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Nirsevimab
9.4. Virazole
9.5. Palivizumab
9.6. Riba Tab
9.7. Others
10. By Dosage Form
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
10.1.2. Market Attractiveness Index, By Dosage Form
10.2. Oral
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Injectable
10.4. Inhaler
10.5. Others
11. By Treatment Type
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.1.2. Market Attractiveness Index, By Treatment Type
11.2. Immune prophylaxis
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Supportive care
11.4. Antiviral Medications
12. By Distribution Channel
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.1.2. Market Attractiveness Index, By Distribution Channel
12.2. Hospital Pharmacy
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Retail Pharmacy
12.4. Online Pharmacy
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. The U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. The U.K.
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. Australia
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Market Share Analysis
14.3. Mergers and Acquisitions Analysis
15. Company Profiles
15.1. Sanofi
15.1.1. Company Overview
15.1.2. Type Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. GSK plc
15.3. Pfizer
15.4. AstraZeneca
15.5. AbbVie
15.6. Bausch Health Companies
15.7. Bavarian Nordic
15.8. Merck & Co
15.9. Moderna, Inc.
15.10. mAbxience.
LIST NOT EXHAUSTIVE
16. Appendix
16.1. About Us and Services
16.2. Contact Us